Glutathione S-transferase Pi expression in invasive breast cancer and its relation with the clinical outcome

Journal of B.U.ON.

Volumn 17, Issue 2, 2012, Pages 259-264

  Franco, Ricardo Laier ^a   Schenka, N G M ^a   Schenka, A A ^a   Rezende, L F ^a   Gurgel, M S C ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Breast cancer; Glutathione S transferase; Immunohistochemistry; Prognosis; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; HORMONE RECEPTOR; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PHENOTYPE; PROTEIN EXPRESSION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; GLUTATHIONE S-TRANSFERASE PI; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE;

EID: 84863611597     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. National Cancer Institute 2011. Cancer incidence estimation in Brazil for 2010/2011. Available at: www.inca.gov.br/estimativa/2011. Assessed in 12 September 2011.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin 2008; 58: 71-96.
3. Jones AL. Reduction in mortality from breast cancer (editorial). BMJ 2005; 330: 205-206. (Pubitemid 40188063)
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
5. Colleoni M, Gelber RD, Gelber S et al. How to improve timing and duration of adjuvant chemotherapy. The Breast 2001; 10 (Suppl 3): 101-105. (Pubitemid 32694539)
6. Huang J, Tan P, Thiyagarajan J et al. Prognostic significance of glutathione S-transferase-Pi in invasive breast cancer. Mod Pathol 2003; 16: 558-565. (Pubitemid 36718437)
7. Lizard-Nacol S, Coudert B, Colosetti P et al. Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer. Breast Cancer Res 1999; 1: 81-87. (Pubitemid 32223550)
8. Board PG, Baker RG, Chelvanayagam G et al. Zeta, a novel class of glutathione transferases in a range of species from plants to humans. Biochem J 1997; 328: 929-935. (Pubitemid 28005795)
9. Mannervik B. The isoenzymes of glutathione S-transferase. Adv Enzymol 1985; 57: 357-417.
10. Ketterer B. Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. Mutat Res 1988; 202: 343-361.
11. Gamesik MP, Millis KK, Colvin OM. Noninvasive detection of elevated glutathione levels in MCF-7 cells resistant to 4-hydroperoxycyclophosphamide. Cancer Res 1995; 55: 2012-2016.
12. Wang K, Ramji S, Bhathena A et al. Glutathione S-transferases in wild-type and doxorubicin-resistant MCF-7 human breast cancer cell lines. Xenobiotica 1999; 29: 155-170. (Pubitemid 29103586)
13. Peters WHM, Roelofs HMJ, Putten WLJ et al. Response to adjuvant chemotherapy in primary breast cancers: no correlation with expression of glutathione S-transferase. Br J Cancer 1993; 68: 86-92. (Pubitemid 23178556)
14. Cairns J, Wright C, Cattan AR et al. Immunohistochemical demonstration of glutathione S-transferases in primary human breast carcinomas. J Pathol 1992; 166: 19-25.
15. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-377.
16. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: the value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 1991; 19: 403-410.
17. Fitzgibbons PL, Page DL, Weaver D et al. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-978.
18. Rhodes A, Jasani B, Anderson E et al. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 2002; 11: 408-417. (Pubitemid 37046339)
19. College of American Pathologists 2008. Available at www.cap.org. Assessed in 12 September 2011.
20. Morris SR, Carey LA. Molecular profiling in breast cancer. Rev Endocr Metab Disord 2007; 8: 185-198. (Pubitemid 47524869)
21. Pusztai L. Current status of prognostic profiling in breast cancer. The Oncologist 2008; 13: 350-360. (Pubitemid 351679913)
22. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEJM 2005; 353: 1659-1672. (Pubitemid 41464705)
23. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. NEJM 2005; 353: 1673-1684. (Pubitemid 41464706)
24. Bai F, Nakanishi Y, Kawasaki M et al. Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with non small cell lung carcinoma. Cancer 1996; 78: 416-421. (Pubitemid 26250525)
25. Shiga H, Heath EI, Rasmussen AA et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 1999; 5: 4097-4104. (Pubitemid 30013791)
26. Hirazono K, Shinozuka T, Kuroshima Y et al. Immunohistochemical expression of glutathione S-transferase pi (GST-pi) and chemotherapy response in malignant ovarian tumors. J Obstet Gynaecol 1995; 21: 305-312.
27. Hamada S, Kamada M, Furumoto H et al. Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol 1994; 52: 313-319.
28. Saip P, Tuzlali S, Demir K et al. Value of glutathione S-transferase pi as a prognostic factor in epithelial ovarian carcinoma. Eur J Gynaecol Oncol 2005; 26: 90-94. (Pubitemid 40314077)
29. Kwon HC, Roh MS, Oh SY et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007; 18: 504-509. (Pubitemid 46359630)
30. Monden N, Abe S, Sutoh I et al. Prognostic significance of the expressions of metallothionein, glutathione-S-transferase-pi, and P-glycoprotein in curatively resected gastric cancer. Oncology 1997; 54: 391-399. (Pubitemid 27321118)
31. Saip R, Sen F, Vural B et al. Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients. J BUON 2011; 16: 241-246.
32. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445-600.
33. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology. Breast cancer - version 1.2008. Available at: www.nccn.org/ professionals/physician-gls/PDF/breast.pdf. Assessed in 12 September 2011.